Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
| Autor: | Kris De Boeck, Bat El Bar Aluma, I. Sarouk, Moshe Ashkenazi, Adi Dagan, L. Bentur, Saray Sity, Ori Efrati, Yael Bezalel |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine medicine.medical_specialty Omalizumab Immunoglobulin E Gastroenterology Cystic fibrosis Aspergillus fumigatus 03 medical and health sciences 0302 clinical medicine Internal medicine Journal of Asthma and Allergy Immunology and Allergy Medicine Eosinophilia Asthma Original Research biology business.industry Retrospective cohort study CF ABPA biology.organism_classification medicine.disease 030104 developmental biology 030228 respiratory system biology.protein IgE Allergic bronchopulmonary aspergillosis medicine.symptom business medicine.drug |
| Zdroj: | Journal of Asthma and Allergy |
| ISSN: | 1178-6965 |
| Popis: | MosheAshkenazi,1,2SaraySity,2 IfatSarouk,1,2Bat El Bar Aluma,1,2AdiDagan,1,2YaelBezalel,1,2LeaBentur3 KrisDe Boeck,4 OriEfrati1,2 1Pediatric Pulmonology and National CF Center, Edmond and Lilly Safra Children’s Hospital, Sheba Medical Center, Ramat Gan, Israel; 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 3Pediatric Pulmonology Institute, Ruth Rappaport Children’s Hospital, Rambam Health Care Campus, Haifa, Israel; 4Pediatric Pulmonology, Department of Pediatrics, University of Leuven, Leuven, Belgium Background: Allergic bronchopulmonary aspergillosis (ABPA) is a condition characterized by a Th2 response, serum eosinophilia, and increased total serum IgE to Aspergillus fumigatus. ABPA occurs in cystic fibrosis (CF) and asthma. Omalizumab is a humanized recombinant monoclonal antibody against IgE. Previous studies reported borderline results when treating ABPA with omalizumab. Methods: A retrospective study to investigate the efficacy of omalizumab in the treatment of ABPA in CF patients was conducted at 3 CF centers in Israel and Belgium. Data were obtained from the digital archive. We measured 4 outcome parameters: forced expiratory volume in 1 second, body mass index, pulmonary exacerbations, and steroid sparing. Results: The database was composed on the records of 9 patients. None of the outcome parameters showed any improvement. A favorable outcome was observed in patients with higher levels of posttreatment total IgE than those with lower levels. CF-related diabetes and male gender showed trends for poorer outcomes. Conclusion: No benefits were detected on treating ABPA in CF with omlaizumb. Monitoring the total IgE was not helpful. A prospective randomized double-blind study is needed. Keywords: ABPA, Omalizumab, CF, IgE |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|